KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Asset Writedowns and Impairment (2017 - 2024)

Historic Asset Writedowns and Impairment for Bionano Genomics (BNGO) over the last 6 years, with Q3 2024 value amounting to $7.2 million.

  • Bionano Genomics' Asset Writedowns and Impairment changed N/A to $7.2 million in Q3 2024 from the same period last year, while for Dec 2024 it was $7.6 million, marking a year-over-year change of. This contributed to the annual value of $7.2 million for FY2024, which is N/A changed from last year.
  • Latest data reveals that Bionano Genomics reported Asset Writedowns and Impairment of $7.2 million as of Q3 2024.
  • In the past 5 years, Bionano Genomics' Asset Writedowns and Impairment registered a high of $7.2 million during Q3 2024, and its lowest value of $44000.0 during Q3 2020.
  • For the 3-year period, Bionano Genomics' Asset Writedowns and Impairment averaged around $1.4 million, with its median value being $475000.0 (2020).
  • The largest annual percentage gain for Bionano Genomics' Asset Writedowns and Impairment in the last 5 years was 1439.39% (2020), contrasted with its biggest fall of 1439.39% (2020).
  • Quarter analysis of 3 years shows Bionano Genomics' Asset Writedowns and Impairment stood at $475000.0 in 2020, then grew by 29.68% to $616000.0 in 2022, then soared by 1068.83% to $7.2 million in 2024.
  • Its last three reported values are $7.2 million in Q3 2024, $448000.0 for Q1 2024, and $616000.0 during Q4 2022.